Get started
Author

Tsz Hong Yiu

Observed name: T H Yiu
ORCID: 0000-0002-0438-0739
Observed ORCID: 0000-0002-0438-0739
OpenAlex ID: A5087097747
Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
2024 · Tsz Hong Yiu, Yanna Ko, et al. · Alimentary Pharmacology & Therapeutics · 42
Nutritional assessment of patients with liver cirrhosis in the outpatient setting: A narrative review
2024 · Stuart Bartlett, Tsz Hong Yiu, et al. · Nutrition · 11
Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol
2023 · Tsz Hong Yiu, Yanna Ko, et al. · BMJ Open · 5
PDF
Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib
2024 · Tsz Hong Yiu, Elizabeth Chow, et al. · Internal Medicine Journal · 3
Letter: Persisting with persistence—A caution as an outcome measure in inflammatory bowel disease: Authors' reply
2024 · Tsz Hong Yiu, Yanna Ko, et al. · Alimentary Pharmacology & Therapeutics · 2
PDF
An assessment of patient readiness to engage in digital patient reported outcomes in an Australian inflammatory bowel disease cohort
2025 · Tsz Hong Yiu, Sarah Rouse, et al. · Health Informatics Journal · 1
Contemporary epidemiology and real-world management of hepatocellular carcinoma (HCC) in Australia: insights from a prospective Australian National Clinical Quality Registry
2026 · Jonathan Abdelmalak, John S. Lubel, et al. · Hepatology International
Adalimumab around the world: comparative analysis of products characteristics and patient support systems
2025 · Tsz Hong Yiu, Emilia Anderson, et al. · Therapeutic Advances in Gastroenterology
Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease—Authors' reply
2024 · Tsz Hong Yiu, Yanna Ko, et al. · Alimentary Pharmacology & Therapeutics
PDF
Su1732 USTEKINUMAB VERSUS INFLIXIMAB AND ADALIMUMAB IN THE REAL-WORLD PERSISTENCE IN CROHN'S DISEASE - A META-ANALYSIS
2023 · Tsz Hong Yiu, Yanna Ko, et al. · Gastroenterology
PDF
P564 vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn’s disease – a meta-analysis
2023 · T H Yiu, R Leong, et al. · Journal of Crohn s and Colitis
PDF
Works count: 12
Citation count: 64
H-index: 3
I10-index: 2
Year
Topic
Type